View at Publisher | View at Google Scholar Ahmed AS et al
FDA's evaluation concluded that the criteria weighed against placement on the list, citing inadequate physicochemical characterization, immunogenicity concerns from impurities and aggregates, lack of clinical effectiveness data for any approved use, and absence of published human exposure data for the proposed subcutaneous and topical routes
There is no established research on long-term, uninterrupted human use, so cycling is the prudent approach
Gray values were determined in regions of interest and measured bilaterally
Weight loss categories were selected a priori using clinically established thresholds [15, 16]: 10% loss (larger loss
In addition to the colonization of the colon by butyrogenic bacteria, it has been proposed that cross-feeding interactions between Bifidobacterial strains and F